Summary
Medtronic plc (MDT) filed an 8-K on December 13, 2018, to report the entry into a material definitive agreement concerning an Amended and Restated Credit Agreement. This new agreement, dated December 12, 2018, establishes a $3.5 billion five-year unsecured revolving credit facility for Medtronic Global Holdings S.C.A., with options for two one-year extensions. The facility is intended for general corporate purposes and to backstop Medtronic's commercial paper program, indicating a strategic move to maintain robust liquidity and financial flexibility. The agreement replaces a prior credit facility and is backed by guarantees from Medtronic plc and Medtronic, Inc. The terms include competitive interest rates tied to the company's debt ratings and a commitment fee on unused portions. This update reassures investors about Medtronic's proactive approach to managing its capital structure and ensuring access to funding for ongoing operations and strategic initiatives.
Key Highlights
- 1Medtronic Global Holdings S.C.A. entered into an Amended and Restated Credit Agreement on December 12, 2018.
- 2The agreement establishes a new $3.5 billion, five-year unsecured revolving credit facility.
- 3The credit facility includes two one-year extension options, providing flexibility.
- 4Funds from the credit facility are intended for general corporate purposes, including backstopping a $3.5 billion commercial paper program.
- 5Medtronic plc and Medtronic, Inc. are guarantors of the obligations under the Credit Agreement.
- 6Borrowing interest rates are based on LIBOR or Alternate Base Rate plus a margin dependent on Medtronic's long-term debt ratings.
- 7A ratings-based commitment fee applies to unused portions of the credit facility.